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Background
Neutralizing antibodies (nAbs) generated during HIV-1
infection are insufficient to protect against a 2nd (dual)
infection; yet, little is known regarding the effect of a 2nd
infection on the anti-HIV-1 nAb response. Therefore, the
objective of this study was to analyze the effect of dual
infection by subtype-discordant HIV-1 strains on the
potency and breadth of this nAb response.
Methods
Two sequential plasma samples from 4 dually-intersub-
type-infected subjects, obtained ~6 months before and
>12 months after the 2nd infection was identified, were
tested against 7 heterologous viruses (5 primary isolates
and 2 Tier1 viruses) representing subtypes A1, B, F2, G,
and CRF02_AG in the GHOST cell neutralization assay.
Additionally, 23 singly-infected control subjects matched
for disease stage, CD4 counts, and time between samples
were studied. Plasma was assayed at 1:80 dilution to com-
pare each plasma pair; subsequently, plasma from dually-
infected subjects and 6 control subjects were assessed for
magnitude and specificity of neutralization using plasma
serial dilutions, 1:20–1:640.
Results
At 1:80 plasma dilution, 3 of the 4 dually-infected sub-
jects' plasma obtained after dual infection exhibited sig-
nificantly increased neutralization compared to initial
plasma. Increases in percent neutralization for all 3
plasma pairs against all 7 heterologous viruses were signif-
icant (0.05 > p > 0.001), with the 2nd sample exhibiting
65%–96% neutralization. No control plasmas exhibited
>30% neutralization of any of the heterologous viruses;
thus, there was an overall significant difference between
case and control subject-sets (p = 0.009). Fifty percent
neutralization titers (IC50) of plasma obtained after dual
infection from the 3 dually-infected subjects exhibited
~6X–100X increases compared to the initial samples
(0.05 > p > 0.0001). No differences in the magnitudes of
neutralization were observed for any of the singly-
infected, control sample pairs.
Conclusion
These data propose that re-infection by a subtype-discord-
ant virus broadens the anti-HIV-1 immune response, sug-
gesting that vaccines incorporating and/or boosting with
subtype-discordant immunogens may generate signifi-
cantly improved anti-HIV-1 immunity.
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